Akebia Therapeutics (AKBA) 8.09 $AKBA Why Akebia

New Post Public Reply Private Reply Replies (0) Message Board

Sep 1, 2016 at 11:18 AM

Akebia Therapeutics (AKBA) 8.09 $AKBA

Why Akebia Therapeutics (AKBA) Could Be Positioned for a Slump
Zacks Equity Research - Zacks Investment Research - Fri Aug 12, 7:40AM CDT
Akebia Therapeutics (AKBA) has witnessed a significant price decline in the past four weeks, and it has lately seen negative earnings estimate revisions as well.
AKBA: 8.09 (-0.04)

Noteworthy Tuesday Option Activity: AKBA, LGF, D
DividendChannel.com - Tue Aug 09, 11:49AM CDT
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Akebia Therapeutics Inc , where a total volume of 1,379 contracts has been traded thus far today, a contract volume which is...
AKBA: 8.09 (-0.04)

Akebia Announces Second Quarter 2016 Financial Results
BusinessWire - Mon Aug 08, 3:15PM CDT
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced financial results for the second quarter ended June 30, 2016.
AKBA: 8.09 (-0.04)

Akebia Initiates INNO2VATE Phase 3 Program for Vadadustat in Dialysis Patients With Anemia Related to Chronic Kidney Disease
BusinessWire - Mon Aug 08, 3:01PM CDT
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced that the company has initiated a global Phase 3 program to evaluate vadadustat for a second indication in renal anemia. Known as INNO2VATE, the program consists of two studies designed to evaluate vadadustat in patients with anemia related to chronic kidney disease who are undergoing dialysis. Akebia's ongoing Phase 3 PRO2TECT program in non-dialysis dependent patients with anemia related to chronic kidney disease commenced at the end of last year.
AKBA: 8.09 (-0.04)

Commit To Buy Akebia Therapeutics At $7.50, Earn 20% Annualized Using Options
StockOptionsChannel.com - Wed Aug 03, 10:43AM CDT
Investors considering a purchase of Akebia Therapeutics Inc stock, but tentative about paying the going market price of $8.78/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put...
AKBA: 8.09 (-0.04)

Akebia Therapeutics Appoints Scott A. Canute to its Board of Directors
BusinessWire - Tue Aug 02, 4:00PM CDT
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced that Scott A. Canute, former President of Global Manufacturing and Corporate Operations of Genzyme Corporation, has been appointed to Akebia's Board of Directors.
AKBA: 8.09 (-0.04)

Akebia Announces Positive Vadadustat Data Demonstrating No Clinically Significant Drug-Drug Interaction
BusinessWire - Mon May 23, 6:00AM CDT
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia inducible factor (HIF), today presented positive results from a drug-drug interaction study of vadadustat, the Company's oral therapy for the treatment of anemia related to chronic kidney disease (CKD). The study demonstrated that vadadustat has no clinically significant interaction with CYP2C9-sensitive substrates and, therefore, may be administered with medications metabolized by CYP2C9 without the need to modify the dose of the co-administered drug. CYP2C9 is involved in the metabolism of many commonly prescribed drugs, such as cholesterol and blood pressure medications. These results were presented at the 53rd European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Congress in Vienna, Austria.
AKBA: 8.09 (-0.04)

Akebia to Present at the 2016 UBS Global Healthcare Conference
BusinessWire - Mon May 16, 6:00AM CDT
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients through the biology of hypoxia-inducible factor (HIF), today announced that John P. Butler, President and Chief Executive Officer, will present at the 2016 UBS Global Healthcare Conference on Monday, May 23, 2016, at 4:00 p.m. Eastern Time. The conference is being held at the Grand Hyatt Hotel in New York City.
AKBA: 8.09 (-0.04)

Akebia Therapeutics reports 1Q loss
Automated Insights - Thu May 05, 5:04PM CDT
CAMBRIDGE, Mass. (AP) _ Akebia Therapeutics Inc. (AKBA) on Thursday reported a loss of $25.8 million in its first quarter.
AKBA: 8.09 (-0.04)

Akebia Announces First Quarter 2016 Financial Results and Provides Corporate Update
BusinessWire - Thu May 05, 3:05PM CDT
--- Announces Positive Data from Japanese Ethnobridging Study for Vadadustat -
AKBA: 8.09 (-0.04)

Commit To Purchase Akebia Therapeutics At $7.50, Earn 30.1% Annualized Using Options
StockOptionsChannel.com - Wed May 04, 10:48AM CDT
Investors eyeing a purchase of Akebia Therapeutics Inc shares, but tentative about paying the going market price of $9.25/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put...
AKBA: 8.09 (-0.04)

Akebia Therapeutics Announces Presentation of Vadadustat Phase 2 Dialysis Data at Upcoming National Kidney Foundation 2016 Spring Clinical Meetings
BusinessWire - Tue Apr 26, 6:00AM CDT
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia inducible factor (HIF), today announced that Phase 2 results for vadadustat in dialysis patients with anemia related to chronic kidney disease (CKD), including new pharmacokinetic data, will be presented in a poster presentation at the National Kidney Foundation 2016 Spring Clinical Meetings taking place in Boston from April 27-May 1.
AKBA: 8.09 (-0.04)

Akebia Therapeutics (AKBA): Strong Industry, Solid Earnings Estimate Revisions
Zacks Equity Research - Zacks Investment Research - Tue Apr 05, 7:57AM CDT
Akebia Therapeutics (AKBA) is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective
AKBA: 8.09 (-0.04)

Akebia to Present at the 15th Annual Needham Healthcare Conference
BusinessWire - Tue Apr 05, 6:00AM CDT
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced that John P. Butler, President and Chief Executive Officer, will present at the 15th Annual Needham Healthcare Conference on Tuesday, April 12, 2016, at 10:00 a.m. Eastern Time. The conference is being held at The Westin Grand Central Hotel in New York City.
AKBA: 8.09 (-0.04)

Commit To Buy Akebia Therapeutics At $5, Earn 20.3% Annualized Using Options
StockOptionsChannel.com - Wed Feb 03, 10:43AM CST
Investors considering a purchase of Akebia Therapeutics Inc stock, but cautious about paying the going market price of $7.41/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put...
AKBA: 8.09 (-0.04)

Akebia to Present at the 18th Annual BIO CEO & Investor Conference
BusinessWire - Mon Feb 01, 6:00AM CST
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced that John P. Butler, President and Chief Executive Officer, will present at the 18th Annual BIO CEO & Investor Conference on Monday, February 8, 2016, at 11:30 a.m. Eastern Time. The conference is being held at The Waldorf Astoria hotel in New York City.
AKBA: 8.09 (-0.04)

Smart Money Highlights Oversold Stocks in Small Cap Biotechs
ACCESSWIRE - Tue Jan 19, 10:22AM CST
NEW YORK, NY / ACCESSWIRE / January 19, 2016 / Biotech has taken a big hit so far in 2016. At the turn of the New Year, the iShares Nasdaq Biotechnology (NASDAQ:IBB) traded at $340. At the end of last week, the index closed out at $284 - a 16% decline across a two-week period. Some companies, of course, have suffered more than others. This is especially true in the development stage as investors pull capital out of riskier small caps. Not all companies warrant their declines, however, and market weakness looks to have left a few stocks oversold. At times like these, following the smart money can help us to identify the oversolds. Here are four companies with top investor backing that could be trading at a significant discount.
VRTX: 94.00 (-0.51), CRBP: 4.16 (+0.07), RPRX: 1.99 (-0.04), IBB: 279.36 (-1.53), AKBA: 8.09 (-0.04), EPZM: 7.25 (-0.06)

Why You Shouldn't Bet Against Akebia Therapeutics (AKBA) Stock
Zacks Equity Research - Zacks Investment Research - Thu Jan 14, 7:44AM CST
Akebia Therapeutics (AKBA) is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
AKBA: 8.09 (-0.04)

Biotech On the Edge? Try Better-Performing Health Care ETFs
Zacks Equity Research - Zacks Investment Research - Tue Jan 12, 12:02PM CST
The year 2016 started with another spell of biotech meltdown. Look at these health care ETFs that were relatively better performers in the stressed space.
IHF: 121.87 (-1.06), BBC: 19.97 (-0.05), SPY: 216.10 (-1.28), IBB: 279.36 (-1.53), EPZM: 7.25 (-0.06), AKBA: 8.09 (-0.04), IHI: 142.50 (-0.85), IXJ: 100.61 (-0.40), XLV: 72.36 (-0.40)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

HONA Faces Legal Heat: Investor Lawsuit Over Losses

The Investor Storm Brewing Over Honeywell Aerospace There it is again, another industry heavyweight caught in a dizzying whirlwind of litigation. Honeywell Aerospace Inc. (NASDAQ:HONA), a name as established as an old boot in the business, now faces a class action lawsuit that's got investors frantically dusting off phone numbers for their attorneys. The Messy Allegations...

Quay Sunglasses: Luxury Looks, Affordable Prices

Ah, sunglasses—the quintessential accessory that screams both practicality and style. A million-dollar look without the million-dollar expense? That's where Quay comes in. They've been recognized by Expert Consumers, no less, as some of the best-in-class for affordable luxury eye candy out there—aimed at shoppers who want the designer vibe without the hemorrhaging...

AI and Storytelling Make Waves in Science Education

University's Innovative Approach to Learning Alright, here's something you don't see every day. The University of Phoenix managed to snag some kudos from an academic journal for using AI and storytelling to teach environmental science. That's like hitting two bulls-eyes with one shot in the world of education. The recognition from Glacies for this Editor's Choice paper...

Krispy Kreme Faces Legal Probe: Fiduciary Breach?

Diving Deep into the Krispy Kreme Allegations Look, this isn't your run-of-the-mill donut drama. When you hear rumblings of corporate missteps, especially ones that involve potential breaches of fiduciary duties, it's time to perk up those ears. Over at Krispy Kreme, Inc. (NASDAQ:DNUT), there's some heat in the kitchen, and it's not just from frying those glazed beauties....

Geron Corp Faces Fiduciary Duty Investigation

Spotlight on Geron's Corporate Governance: What's Happening? The heat's been turned up on Geron Corporation this week, with Halper Sadeh LLC, an investor rights law outfit, digging into whether some folks at the helm have strayed from their fiduciary duties to the shareholders. Now, if you're holding onto NASDAQ:GERN stock or thinking about diving in, it's high time to...

CVS Health Under Fire: Fiduciary Duty Breach?

CVS Under Regulatory Spotlight for Fiduciary Breaches You'd think by now companies would have their fiduciary ducks in a row. But here we are, with CVS Health Corporation (NYSE: CVS) catching heat from the legal eagles over at Halper Sadeh LLC. The knife’s out for some of the big wigs – apparently, there's chatter they might’ve slipped on their duty to play nice...

Timur Turlov Leads FIDE with Chess and Digital Focus

An Unpredicted Victory in Samarkand Well, color me surprised. Timur Turlov's made waves by clinching the role of FIDE President at the General Assembly in Samarkand. This one's quite the turn for the chess world—Kazakhstan’s own stepping up to run the whole show. This isn't just some ceremonial post either. Turlov, who's been pulling strings over at the Kazakhstan...

Jackson Wang's Fantasy IP Hits Hong Kong Stage

A Star-Studded Fantasy Comes Alive Hong Kong isn't just about dim sum and skyline views—it's a magnet for celebrity showcases, and this time, Jackson Wang's pulling the strings. The guy's ventured beyond music and idol fame, diving head-first into creative visuals with his fantasy IP, "Under the Castle" (UTC). Pairing up with Ocean Park's Halloween Fest, he's cooked up...

PACS Group Faces Legal Scrutiny: What to Watch

PACS Group: Legal Storm Brewing Welcome to the latest saga in the volatile theater of corporate governance. PACS Group, Inc., ticker symbol NYSE:PACS, is under the microscope, and not for debuting a groundbreaking product or hitting a stock milestone. Nope, instead we've got Halper Sadeh LLC out of New York investigating some possible hanky-panky from PACS directors and...

Endurance Energy's Modular Tech Revs Up Southeast Asia

Modular Solutions Steal the Show in Bangkok When a company draws 59,468 attendees from over 150 countries, folks pay attention—and that was exactly the scene at Gastech 2026 in Bangkok. The name buzzing on many lips? Endurance Energy. These guys showcased a fresh take on energy logistics with their skid-mounted liquefaction tech, turning heads with their Southeast Asia...